Your browser doesn't support javascript.
loading
Expanding controlled donation after the circulatory determination of death: statement from an international collaborative.
Domínguez-Gil, Beatriz; Ascher, Nancy; Capron, Alexander M; Gardiner, Dale; Manara, Alexander R; Bernat, James L; Miñambres, Eduardo; Singh, Jeffrey M; Porte, Robert J; Markmann, James F; Dhital, Kumud; Ledoux, Didier; Fondevila, Constantino; Hosgood, Sarah; Van Raemdonck, Dirk; Keshavjee, Shaf; Dubois, James; McGee, Andrew; Henderson, Galen V; Glazier, Alexandra K; Tullius, Stefan G; Shemie, Sam D; Delmonico, Francis L.
Afiliación
  • Domínguez-Gil B; Director General, Organización Nacional de Trasplantes, Madrid, Spain.
  • Ascher N; Department of Surgery, University of California, San Francisco, CA, USA.
  • Capron AM; Scott H. Bice Chair in Healthcare Law, Policy and Ethics, Department of Medicine and Law, University of Southern California, Los Angeles, CA, USA.
  • Gardiner D; Intensive Care Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Manara AR; Consultant in Intensive Care Medicine, The Intensive Care Unit, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
  • Bernat JL; Department of Neurology and Medicine, Active Emeritus, Dartmouth Geisel School of Medicine, Hanover, NH, USA.
  • Miñambres E; Transplant Coordination Unit and Service of Intensive Care, University Hospital Marqués de Valdecilla-IDIVAL, School of Medicine, University of Cantabria, Santander, Spain.
  • Singh JM; University of Toronto, and Trillium Gift of Life Network, Toronto, Canada.
  • Porte RJ; Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands.
  • Markmann JF; Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
  • Dhital K; Department of Cardiothoracic Surgery, Sant Vincent'S Hospital, Sidney, Australia.
  • Ledoux D; Department of Anesthesia and Intensive Care, University of Liège, Liège, Belgium.
  • Fondevila C; General and Digestive Surgery, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.
  • Hosgood S; Department of Surgery, University of Cambridge, Cambridge, UK.
  • Van Raemdonck D; University Hospitals Leuven and Catholic University Leuven, Leuven, Belgium.
  • Keshavjee S; Toronto General Hospital, University of Toronto, Toronto, Canada.
  • Dubois J; Bioethics Research Center, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • McGee A; Australian Centre for Health Law Research, Faculty of Law, Queensland University of Technology, Brisbane City, Australia.
  • Henderson GV; Director of Neurocritical Care, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Glazier AK; Chief Executive Officer, New England Donor Services, Walthan, MA, USA.
  • Tullius SG; Division of Transplant Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Shemie SD; Pediatric Intensive Care, Montreal Children's Hospital, McGill University, Medical Advisor, Deceased Donation, Canadian Blood Services, Montreal, Canada.
  • Delmonico FL; Chief Medical Officer, New England Donor Services, 60 1st Ave, Waltham, MA, 02451, USA. Francis_Delmonico@neds.org.
Intensive Care Med ; 47(3): 265-281, 2021 Mar.
Article en En | MEDLINE | ID: mdl-33635355
ABSTRACT
A decision to withdraw life-sustaining treatment (WLST) is derived by a conclusion that further treatment will not enable a patient to survive or will not produce a functional outcome with acceptable quality of life that the patient and the treating team regard as beneficial. Although many hospitalized patients die under such circumstances, controlled donation after the circulatory determination of death (cDCDD) programs have been developed only in a reduced number of countries. This International Collaborative Statement aims at expanding cDCDD in the world to help countries progress towards self-sufficiency in transplantation and offer more patients the opportunity of organ donation. The Statement addresses three fundamental aspects of the cDCDD pathway. First, it describes the process of determining a prognosis that justifies the WLST, a decision that should be prior to and independent of any consideration of organ donation and in which transplant professionals must not participate. Second, the Statement establishes the permanent cessation of circulation to the brain as the standard to determine death by circulatory criteria. Death may be declared after an elapsed observation period of 5 min without circulation to the brain, which confirms that the absence of circulation to the brain is permanent. Finally, the Statement highlights the value of perfusion repair for increasing the success of cDCDD organ transplantation. cDCDD protocols may utilize either in situ or ex situ perfusion consistent with the practice of each country. Methods to accomplish the in situ normothermic reperfusion of organs must preclude the restoration of brain perfusion to not invalidate the determination of death.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Obtención de Tejidos y Órganos / Trasplante de Órganos Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Intensive Care Med Año: 2021 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Obtención de Tejidos y Órganos / Trasplante de Órganos Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Intensive Care Med Año: 2021 Tipo del documento: Article País de afiliación: España